Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Aug;39(8):1885–1887. doi: 10.1128/aac.39.8.1885

Liposomal amphotericin B therapy of murine histoplasmosis.

J R Graybill 1, R Bocanegra 1
PMCID: PMC162848  PMID: 7486941

Abstract

Liposomal amphotericin B (AmBisome) was compared with amphotericin B deoxycholate for the treatment of disseminated murine histoplasmosis. Liposomal amphotericin B was well tolerated and, milligram for milligram, was as potent as amphotericin B deoxycholate.

Full Text

The Full Text of this article is available as a PDF (184.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allendoerfer R., Magee D. M., Deepe G. S., Jr, Graybill J. R. Transfer of protective immunity in murine histoplasmosis by a CD4+ T-cell clone. Infect Immun. 1993 Feb;61(2):714–718. doi: 10.1128/iai.61.2.714-718.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):665–668. doi: 10.1007/BF01975823. [DOI] [PubMed] [Google Scholar]
  3. Brajtburg J., Powderly W. G., Kobayashi G. S., Medoff G. Amphotericin B: delivery systems. Antimicrob Agents Chemother. 1990 Mar;34(3):381–384. doi: 10.1128/aac.34.3.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dismukes W. E., Stamm A. M., Graybill J. R., Craven P. C., Stevens D. A., Stiller R. L., Sarosi G. A., Medoff G., Gregg C. R., Gallis H. A. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med. 1983 Jan;98(1):13–20. doi: 10.7326/0003-4819-98-1-13. [DOI] [PubMed] [Google Scholar]
  5. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Karyotakis N. C., Anaissie E. J. Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice. Antimicrob Agents Chemother. 1994 Nov;38(11):2660–2662. doi: 10.1128/aac.38.11.2660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother. 1987 May;31(5):675–678. doi: 10.1128/aac.31.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. McBride M., Linney M., Claydon E. J., Weber J. Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis. 1994 Aug;19(2):362–362. doi: 10.1093/clinids/19.2.362. [DOI] [PubMed] [Google Scholar]
  9. Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):83–91. doi: 10.1093/jac/28.suppl_b.83. [DOI] [PubMed] [Google Scholar]
  10. Norris S., Wheat J., McKinsey D., Lancaster D., Katz B., Black J., Driks M., Baker R., Israel K., Traeger D. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. Am J Med. 1994 Jun;96(6):504–508. doi: 10.1016/0002-9343(94)90089-2. [DOI] [PubMed] [Google Scholar]
  11. Pahls S., Schaffner A. Comparison of the activity of free and liposomal amphotericin B in vitro and in a model of systemic and localized murine candidiasis. J Infect Dis. 1994 May;169(5):1057–1061. doi: 10.1093/infdis/169.5.1057. [DOI] [PubMed] [Google Scholar]
  12. Schmitt H. J. New methods of delivery of amphotericin B. Clin Infect Dis. 1993 Nov;17 (Suppl 2):S501–S506. doi: 10.1093/clinids/17.supplement_2.s501. [DOI] [PubMed] [Google Scholar]
  13. Sharkey-Mathis P. K., Velez J., Fetchick R., Graybill J. R. Histoplasmosis in the acquired immunodeficiency syndrome (AIDS): treatment with itraconazole and fluconazole. J Acquir Immune Defic Syndr. 1993 Jul;6(7):809–819. [PubMed] [Google Scholar]
  14. Tucker R. M., Denning D. W., Hanson L. H., Rinaldi M. G., Graybill J. R., Sharkey P. K., Pappagianis D., Stevens D. A. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992 Jan;14(1):165–174. doi: 10.1093/clinids/14.1.165. [DOI] [PubMed] [Google Scholar]
  15. Wheat J., Hafner R., Wulfsohn M., Spencer P., Squires K., Powderly W., Wong B., Rinaldi M., Saag M., Hamill R. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1993 Apr 15;118(8):610–616. doi: 10.7326/0003-4819-118-8-199304150-00006. [DOI] [PubMed] [Google Scholar]
  16. Wheat L. J., Connolly-Stringfield P. A., Baker R. L., Curfman M. F., Eads M. E., Israel K. S., Norris S. A., Webb D. H., Zeckel M. L. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990 Nov;69(6):361–374. doi: 10.1097/00005792-199011000-00004. [DOI] [PubMed] [Google Scholar]
  17. Williams D. M., Graybill J. R., Drutz D. J. Adoptive transfer of immunity to Histoplasma capsulatum in athymic nude mice. Sabouraudia. 1981 Mar;19(1):39–48. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES